scispace - formally typeset
W

Walter Berger

Researcher at Medical University of Vienna

Publications -  396
Citations -  16667

Walter Berger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cancer & Cell culture. The author has an hindex of 63, co-authored 359 publications receiving 14045 citations. Previous affiliations of Walter Berger include University of Vienna & Université libre de Bruxelles.

Papers
More filters
Journal ArticleDOI

Abstract 4901: The role of protein disulfide isomerase and copper in the paraptotic cell death of clinically investigated anticancer thiosemicarbazones

TL;DR: Hager et al. as discussed by the authors investigated the molecular signaling behind paraptosis as well as the reasons behind the induction of this quite unknown form of cell death by TSCs and found an upregulation of the coppersensitive and thiol-containing protein disulfide isomerase (PDI), which was confirmed on protein level.
Journal ArticleDOI

Targeting receptor tyrosine kinases in malignant pleural mesothelioma: Focus on FGF-receptors

TL;DR: FGFR blockade by a tyrosine kinase inhibitor or by a dominant-negative receptor construct resulted in reduced MPM growth in vitro and in vivo and enhanced the efficacy of chemo- or radiotherapy.
Journal ArticleDOI

Epen-11. characterization of the spatial architecture of intratumoral cell states in pediatric high-risk ependymoma

TL;DR: In this article , spatial transcriptomics (10X Visium) of tumor specimens matching their previously generated single-cell transcriptome data spanning all EPN subtypes (ZFTA, YAP1, PFA, PFB) was used to characterize the spatial architecture and elucidate regulatory circuits in EPN via spatial transcriptomic data, which revealed presence of distinct intratumoral cell states within ependymoma tissue and reveal their spatial organization.
Journal ArticleDOI

MODL-14 Inhibition of cell cycle mechanisms to combat high-risk medulloblastoma

TL;DR: The CDK4/6 clinically approved inhibitor abemaciclib shows promising efficacy against high-risk MB in vitro and in vivo, and within the ITCC-P4 project, single mouse trials are currently being performed including abemACiclib treatment in orthotopic MB models.